Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.

Frost, Nikolaj; Christopoulos, Petros; Kauffmann-Guerrero, Diego; Stratmann, Jan; Riedel, Richard; Schaefer, Monica; Alt, Jürgen; Gütz, Sylvia; Christoph, Daniel C; Laack, Eckart; Faehling, Martin; Fischer, Richard; Fenchel, Klaus; Haen, Sebastian; Heukamp, Lukas; Schulz, Christian; Griesinger, Frank

Frost, Nikolaj; Christopoulos, Petros; Kauffmann-Guerrero, Diego; Stratmann, Jan; Riedel, Richard; Schaefer, Monica; Alt, Jürgen; Gütz, Sylvia; Christoph, Daniel C; Laack, Eckart; Faehling, Martin; Fischer, Richard; Fenchel, Klaus; Haen, Sebastian; Heukamp, Lukas; Schulz, Christian; Griesinger, Frank.

Afiliação

Frost N; Department of Infectious Diseases and Respiratory Medicine, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, Berlin, D-13353, Germany Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and Pulmona
Christopoulos P; Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany, and Translational Research Center Heidelberg, Member of the German Center for Lung Research (DZL).
Kauffmann-Guerrero D; Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V University of Munich (LMU), Thoracic Oncology Centre Munich (TOM), Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Munich, Bayern, Germany.
Stratmann J; Department of Internal Medicine II, University Clinic of Frankfurt, Frankfurt, Germany.
Riedel R; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Schaefer M; HELIOS Klinikum Emil-von-Behring, Lungenklinik Heckeshorn, Berlin, Germany.
Alt J; Department of Internal Medicine III (Hematology, Oncology, Pneumology), University Medical Center Mainz, Mainz, Germany.
Gütz S; Department of Respiratory Medicine and Cardiology, Evangelisches Diakonissenkrankenhaus Leipzig, Leipzig, Germany.
Christoph DC; Department of Hematology and Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.
Laack E; Hämato-Onkologie Hamburg, Hamburg, Germany.
Faehling M; Department of Cardiology, Angiology and Pneumonology, Klinikum Esslingen, Esslingen, Germany.
Fischer R; Onkologie Dreiländereck, Lörrach, Germany.
Fenchel K; Private Practice for Hematology and Oncology, Saalfeld, Germany.
Haen S; Department of Hematology and Oncology, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Heukamp L; Institute for Hematopathology, Hamburg, Germany.
Schulz C; Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Griesinger F; Department Internal Medicine-Oncology, Pius Hospital, Oldenburg, Germany.

Ther Adv Med Oncol ; 13: 1758835920980558, 2021.

Article em En | MEDLINE | ID: mdl-33613692

Palavras-chave

ALK; NSCLC; ROS1; TP53; brain metastases; early access program; lorlatinib

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Ano de publicação: 2021 Tipo de documento: Article